Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers by Barbanoj, Manel J. et al.
ORIGINAL INVESTIGATION
Daytime Ayahuasca administration modulates REM
and slow-wave sleep in healthy volunteers
Manel J. Barbanoj & Jordi Riba & S. Clos & S. Giménez &
E. Grasa & S. Romero
Received: 2 May 2007 /Accepted: 19 September 2007 / Published online: 21 November 2007
# Springer-Verlag 2007
Abstract
Objectives Ayahuasca is a traditional South American psy-
choactive beverage and the central sacrament of Brazilian-
based religious groups, with followers in Europe and the
United States. The tea contains the psychedelic indole N,
N-dimethyltryptamine (DMT) and β-carboline alkaloids
with monoamine oxidase-inhibiting properties that render
DMT orally active. DMT interacts with serotonergic
neurotransmission acting as a partial agonist at 5-HT1A
and 5-HT2A/2C receptor sites. Given the role played by
serotonin in the regulation of the sleep/wake cycle, we
investigated the effects of daytime ayahuasca consumption
in sleep parameters.
Measurements and results Subjective sleep quality, poly-
somnography (PSG), and spectral analysis were assessed in
a group of 22 healthy male volunteers after the administra-
tion of a placebo, an ayahuasca dose equivalent to 1 mg
DMT kg−1 body weight, and 20 mg d-amphetamine, a
proaminergic drug, as a positive control. Results show that
ayahuasca did not induce any subjectively perceived
deterioration of sleep quality or PSG-measured disruptions
of sleep initiation or maintenance, in contrast with d-
amphetamine, which delayed sleep initiation, disrupted
sleep maintenance, induced a predominance of ‘light’ vs
‘deep’ sleep and significantly impaired subjective sleep
quality. PSG analysis also showed that similarly to d-
amphetamine, ayahuasca inhibits rapid eye movement
(REM) sleep, decreasing its duration, both in absolute
values and as a percentage of total sleep time, and shows a
trend increase in its onset latency. Spectral analysis showed
that d-amphetamine and ayahuasca increased power in the
high frequency range, mainly during stage 2. Remarkably,
whereas slow-wave sleep (SWS) power in the first night
cycle, an indicator of sleep pressure, was decreased by
d-amphetamine, ayahuasca enhanced power in this fre-
quency band.
Conclusions Results show that daytime serotonergic
psychedelic drug administration leads to measurable
changes in PSG and sleep power spectrum and suggest an
interaction between these drugs and brain circuits modulat-
ing REM and SWS.
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Introduction
Ayahuasca is a psychotropic plant concoction that contains
the psychedelic indole N,N-dimethyltryptamine (DMT) and
has mind-modifying properties that have played a central
role in shaping the world view of the indigenous peoples of
the Amazon (Schultes and Hofmann 1987). The tea is
commonly obtained by infusing the stems of the Banister-
iopsis caapi liana together with the leaves of the Psychotria
viridis bush, and it is used in traditional medicine and
magico-religious practices (Schultes and Hofmann 1987).
In recent times, several synchretic religions known gener-
ically as ‘ayahuasca churches’ have appeared in Brazil,
blending Christian beliefs with the sacramental use of
ayahuasca. These congregations have contributed signifi-
cantly to the introduction of ayahuasca use to the United
States and Europe. The US Supreme Court recently ruled in
favor of allowing one of these churches, the União do
Vegetal, the religious use of ayahuasca among its members,
a status analogous to that held by the Native American
Church for the use of peyote (Lophophora williamsii).
Research into ayahuasca has shown that the tea
combines the orally labile DMT from P. viridis with
monoamine oxidase (MAO)-inhibiting β-carboline alka-
loids (Buckholtz and Boggan 1977b) from B. caapi in a
single preparation. Remarkably, these β-carbolines block
the metabolic breakdown of DMT by the visceral MAO,
allowing its access to systemic circulation (Riba et al.
2003). In the central nervous system, ayahuasca interacts
mainly with serotonergic neurotransmission, with DMT
acting as a partial agonist at the 5-HT1A and 5-HT2A/2C
receptor sites (Deliganis et al. 1991).
In previous studies conducted by our group to character-
ise the pharmacology of ayahuasca, this tea showed a
psychedelic and stimulatory profile compatible with
5-HT2A agonism and pro-aminergic effects. Self-report
questionnaires demonstrated somatic, perceptual and cog-
nitive modifications, together with increases in positive
mood and activation (Riba et al. 2003). Electroencephalog-
raphy measures during wakefulness indicated reductions in
slow (delta and theta) and alpha-2 activity (Riba et al. 2002)
and measures of regional cerebral blood flow showed
increased perfusion in paralimbic and frontal brain regions
(Riba et al. 2006).
Sleep disturbances have been described for recreational
drugs acting on serotonergic neurotransmission, such as 3,4
methylenedioxymethamphetamine (Morgan 2000). Seroto-
nin plays a prominent role in the regulation of sleep–wake
cycles. Both the firing of serotonergic neurons in the raphe
nuclei and serotonin release increase during waking,
decrease in non-REM sleep and are absent during the
REM stage (McGinty and Harper 1976). This regulation
mechanism is very complex and involves the interplay of
several serotonin receptor subtypes, with 5-HT1A agonism
suppressing REM sleep (Driver et al. 1995), 5-HT2A,
5-HT2C antagonism enhancing slow-wave sleep (SWS)
(Landolt et al. 1999) and 5-HT2C agonism decreasing SWS
(Katsuda et al. 1993).
In the present study, we investigated possible sleep
disturbances associated with acute daytime ayahuasca
administration. The sleep effects of daytime ayahuasca
administration were compared vs placebo and vs
d-amphetamine as a positive control. d-Amphetamine
shares with ayahuasca stimulatory properties and an
inhibitory effect on the waking EEG slow activity (delta
and theta) but it lacks the psychedelic effects associated
with serotonergic 5-HT1A and 5-HT2A/2C agonism. Based
on the arousing effects of ayahuasca, we postulated that a
deterioration of sleep initiation, maintenance and subjec-
tive quality would be observed, similar to that previously
reported for d-amphetamine (Saletu et al. 1989). However,
given the pharmacological mechanism responsible for the
psychedelic effects of DMT, i.e., 5-HT2A agonism, we also
postulated that ayahuasca would modulate REM and
slow-wave sleep.
Materials and methods
Volunteers
Twenty-two young healthy male volunteers were recruited.
Mean age was 27.1 years (range 20–38), mean weight was
67.6 kg (range 60–85) and mean height was 1.77 m (range
1.60–1.90). Eligibility criteria included prior use of psy-
chedelics on at least ten occasions without sequelae derived
thereof. The most frequently consumed psychedelics were
LSD and psilocybian mushrooms. All volunteers underwent
a structured psychiatric interview (DMS-IV). Exclusion
criteria included current or past history of Axis-I disorders
and alcohol or other substance dependence. A medical
examination and laboratory tests were performed before
study initiation. All participants were screened for sleep
disturbances (Pittsburg sleep quality index < 5). Pre-study
examinations also included drug screening and serological
testing (for hepatitis B and C and HIV). The alcohol, coffee
and cigarette consumption reported in all volunteers was
insufficient to lead to withdrawal symptoms during the 48-
h period around the experimental session where consump-
tion was not allowed (≤39 g absolute alcohol/day, ≤100 mg
caffeine/day, ≤5 cigarettes/day). No strenuous physical
exercise or naps were allowed in the 24 h before each
experimental session or in the ensuing 24 h. Participants
were requested not to take any medications or illicit drugs
during the study and were asked to keep regular sleep–
wake habits during the fortnight before the study and
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during the study proper. Urine was tested for illicit drug use
on each experimental session.
The study was approved by the local Ethics Committee
and the Spanish Ministry of Health, and was conducted
following the principles stated in the Declaration of
Helsinki and the guidelines of Good Clinical Practice.
All volunteers gave their written informed consent to
participate.
Drugs
The administered drugs were a placebo, 20 mg d-amphet-
amine and a freeze-dried encapsulated formulation of
ayahuasca equivalent to 1 mg DMT/kg body weight. One
gram of lyophilizate contained: 8.33 mg DMT, 14.13 mg
harmine, 0.96 mg harmaline and 11.36 mg tetrahydrohar-
mine (THH) per gram. The calculated individual dose of
ayahuasca for each volunteer was administered by com-
bining gelatine capsules (00 size) containing 0.5, 0.25 or
0.125 g of lyophilizate. Volunteers received the same
number of capsules on each experimental session.
Study design
The study was conducted according to a randomized,
double-blind, placebo-controlled, cross-over design and
involved participation in three experimental sessions at
least 1 week apart, plus an adaptation night in the sleep
laboratory. The adaptation night was used to familiarize the
participants with the laboratory and the recording proce-
dures and was held within the 2 weeks before the first
experimental session. Data from this adaptation night were
not included in the statistical analyses. On each of the three
experimental sessions, volunteers arrived in the laboratory
at 7:00 A.M. and had a light breakfast before 10:00 A.M. At
12:00 noon, they received the capsules containing one of
the three treatments and they then remained in the
laboratory until 12:00 the next day. Volunteers were
constantly supervised and they were not allowed to nap.
Sleep recordings were conducted from 11:00 P.M. of the
experimental session until 7:00 A.M. of the next day. Data
from these three nights were subsequently submitted to
statistical analysis. Additionally, to measure pattern and
intensity of the acute subjective effects induced by
ayahuasca during the day, participants responded self-
report questionnaires before and after 4 h of drug
administration (see below).
Subjective effect measures
Self-rated subjective effects were measured by administer-
ing Spanish versions of the Hallucinogen Rating Scale or
HRS (Riba et al. 2001) and the Addiction Research Center
Inventory or ARCI (Lamas et al. 1994). The HRS measures
psychedelic-induced subjective effects and includes six
scales: somaesthesia, reflecting somatic effects; affect,
sensitive to emotional and affective responses; volition,
indicating the volunteer’s capacity to willfully interact with
his/her ‘self’ and/or the environment; cognition, describing
modifications in thought processes or content; perception,
measuring visual, auditory, gustatory and olfactory experi-
ences; and finally intensity, which reflects the strength of
the overall experience. The range of scores for all HRS
scales is 0 to 4. The ARCI consists of five scales or groups:
MBG, morphine-benzedrine group, measuring euphoria and
positive mood; PCAG, pentobarbital-chlorpromazine-
alcohol group, measuring sedation; LSD, lysergic acid
diethylamide scale, measuring somatic-dysphoric effects;
BG, the benzedrine group, measuring intellectual energy
and efficiency, and the A scale, an empirically derived scale
measuring amphetamine-like effects. The range of scores is
0 to 16 for MBG, −4 to 11 for PCAG, −4 to 10 for LSD, −4
to 9 for BG and 0 to 11 for A. Volunteers answered the
ARCI immediately before drug administration, and 4 h after
drug intake, whereas the HRS was only answered at 4 h
post-administration.
Before statistical analysis, ARCI scores were trans-
formed to differences from pre-administration values. The
transformed ARCI scores and raw HRS scores were
analyzed by means of multivariate and univariate tests as
indicated below.
Recordings and sleep stage classification
Sleep recordings were performed in individual, sound-
attenuated, temperature-regulated rooms and volunteers
were supervised by qualified technical staff. Volunteers
had dinner by 8.00 P.M. and started sleep procedures. The
total time in bed was fixed at 8 h. The lights were turned off
around 11.00 P.M. and turned on around 7 A.M. the next
morning. In addition, the volunteers completed a self-rating
scale on the subjective quality of sleep and awakening no
later than 15 min after having woken up each morning
(Saletu et al. 1987).
Data were acquired by means of either (1) the Coherence
32E-Deltamed system, or (2) the SleepLab-Aequitron
Medical Recordings system; the same system was used
for each volunteer. Recordings consisted of six EEG-
channels (Fp1, Fp2, C3, C4, O1, O2, vs the average of
both mastoids (A1-A2) according to the 10/20 International
System), two electro-oculographic leads (EOG) (right and
left, registered between both external canthi, with a capacity
to detect ocular movements in both directions: horizontal
and vertical), and one chin electromyographic channel
(EMG), consisting of two electrodes placed on the
submentonian muscles, which monitored the muscular tone.
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Three channels were included to monitor the respiratory
function: one for airflow signal (by means of a thermistor
placed in the path of airflow from nose and mouth) and two
channels to record rib cage and abdominal motion (by
calibrated transducers). Finally, two channels (linked
electrodes on the left and right anterior tibialis) were used
to register limb movements. EEG and EOG channels were
filtered to a bandwidth of 0.1–75 Hz with a sensitivity of
10 μV/mm. EMG was filtered to a bandwidth of 10–75 Hz
with a sensitivity of 5 μV/mm. A 50-Hz notch filter was
used to attenuate electrical noise. The electrodes were gold-
plated. Channels were calibrated before each recording and
the electrode impedance was kept below 10 kΩ.
The sleep recordings were visually scored in a 30-s
epoch resolution according to the traditional standard R&K
criteria (Rechtschaffen and Kales 1968) using the View and
Rate (Cdatentechnik GbR, © 1995–1999 3.02 version)
program. Analysis was performed by two independent sleep
scorers. Discrepancies were solved by a third expert from
the same laboratory. Each scorer was blind to the other
raters’ analysis and treatment received by the participant.
Sleep variables were derived by visual scoring using
standard criteria. Total sleep time (TST) is the amount of
actual sleep time in the total sleep period (TSP); equal to
TSP less wakefulness (stage 0). TSP is the total time
available for sleep during an attempt to sleep and comprises
NREM and REM sleep, as well as wakefulness; in addition
to TST, TSP includes stage 0. The number of awakenings
refers to the arousals to wakefulness during TSP. The sleep
efficiency index (SEI) is the proportion of sleep in the
recorded period, and is calculated by dividing TST by the
total time in bed (TIB) and multiplied by 100. Sleep stages
1, 2, slow-wave sleep (3+4) (SWS) and REM are expressed
in minutes and in percentages of the TST. Movement time
is identified when more than a half of the scoring epoch is
obscured because of movement but the preceding and
subsequent epochs are of sleep. Movement time is
expressed in minutes and in percentage of the TST. Latency
to stages 1, 2 and 3 defines the period of time measured
from lights out to the appearance of sleep stages 1, 2 and 3,
respectively. REM latency is defined as clock time from the
first epoch of stage 2 (followed by ≥8 min sleep in the next
10 min) to the first REM period of at least 3 min. In
addition, the number of NREM and REM periods as well as
the average duration of NREM and REM periods and of
sleep cycles was computed. Consecutive NREM-REM
cycles were defined according to modifications of the
criteria proposed by Feinberg and Floyd (1979). NREM
episodes were defined as starting with stage 2, containing at
least 15 min of stages 2, 3 and 4, and being followed by
REM episodes of at least 5-min duration. No minimal
criterion for the REM duration was applied for the
completion of the first cycle.
EEG power spectra
Despite its widespread use in visual scoring, the conven-
tional R&K criteria (Rechtschaffen and Kales 1968)
provides insufficient information about the continuity of
sleep stages. All-night spectral analysis is a sensitive
method for documenting pharmacological effects on sleep
EEG (Borbély et al. 1985). It not only detects shifts
between the various sleep stages during the night, but also
takes into account the qualitative alterations of certain
stages (Schlösser et al. 1998). To conduct spectral analysis,
the EEG signal was high-pass (0.3 Hz) and low-pass
(35 Hz) filtered before being converted from analogue to
digital and the sampling frequency was 256 Hz. Power
spectra of 5-s artefact-free epochs, weighted by a Hanning
window, were computed using the Fast Fourier Transform
and matched with the sleep scores. Epochs containing
artefacts caused either by saturation or muscle activity were
automatically identified and eliminated. Mean (±SEM)
artefact-free recordings, in seconds, computed for the
different experimental nights were: 5.245±50.3 after
placebo, 5.335±30.9 after ayahuasca, and 5.024±88.2,
after d-amphetamine, being 91.4, 93.1 and 87.7% of the
corresponding TIB, respectively. Power density values
(C4A1 derivation) were averaged into 0.4 Hz (0.2–
6.0 Hz) and 0.8 Hz (6.2–26.0 Hz) bins. The spectra were
calculated separately for non-REM sleep (NREMS stages:
1, 2, 3 and 4), stage 2 (S2), slow wave activity (SWS:
stages 3 and 4) and REM sleep (REMS).
Dynamics of slow-wave activity, spindle frequency activity
during whole night and delta EOG activity during REM
sleep
Slow-wave activity (SWA) is defined as the power in the
delta band (0.5–4.0 Hz) and spindle frequency activity
(SFA) as the power in the sigma band (11.0–15.0 Hz) for
the C4A1 derivation during whole night sleep. Delta EOG
activity (DEA) is defined as the power in the delta band
(0.5–4.0 Hz) for the EOG channels during REM sleep.
These variables were computed from 5-s artifact-free
epochs. DEA was used as a representative of phasic
REM activity intensity. A moving average estimation of
5-min duration was computed to smooth the signal
throughout the night.
To compensate for the individual differences in the
occurrence and duration of the NREM–REM cycles, a
method derived from that of Aeschbach and Borbély
was used (Aeschbach and Borbély 1993). For SWA and
SFA, each NREM period of unequal length was sub-
divided into 24 equal parts, and each REM period into
four equal parts. They were then averaged across subjects.
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For DEA, each REM period of unequal length was
subdivided into 24 equal parts and averaged across
subjects. Changes in the three dynamic activities were
evaluated on the raw data by calculating areas under the
curve (AUC) in each cycle.
Sleep and awakening quality self-rating scale
A Spanish version of the ‘Self-assessment Scale for
Sleep and Awakening Quality (SSA)’ (Saletu et al.
1987) was used. The SSA consists of 20 items grouped in
three categories: (1) SSA-1 (seven items), which evaluates
subjective sleep quality; (2) SSA-2 (eight items), evaluat-
ing subjective awakening quality; and (3) SSA-3 (five
items), evaluating the presence of somatic complaints.
Responses are coded according to an ordinal scale with
four possibilities (not at all, slightly, moderately and
extremely). In the coding process, the values 1, 2, 3 or 4
are assigned in such a way that a higher score means a
worse subjective quality, with the theoretical score ranging
from: 20–80 for the global scale (SSA), 7–28 for SSA-1,
8–32 for SSA-2 and 5–20 for SSA-3. Furthermore, the
questionnaire presents five additional open questions
related to different moments of the night, from which
subjective sleep latency (SSL) and subjective sleep
efficiency (SSE) are calculated.
Statistical analysis
To decrease the risk of type I error, PSG variables were
grouped in three different clusters comprising: (1) sleep
initiation and maintenance variables; (2) sleep architecture
variables; and (3) NREM–REM period variables. SSA
variables were grouped in a fourth cluster. Each cluster and
a subjective effect measures cluster obtained from the self-
report questionnaires (HRS and ARCI combined) were
subjected to a multivariate analysis of variance (MANOVA).
Within each cluster, the MANOVA yielded the result of a
general linear model with one within-subject factor (treat-
ment: three levels) for each variable. Greenhouse-Geisser ɛ
correction was used. Pairwise comparisons were conducted
by means of repeated measures t tests corrected for multiple
comparisons (Sidak).
To assess the effects on EEG power spectra at the
different sleep stages and on the AUCs of its dynamics,
repeated measures t tests were applied to each frequency
bin or AUC, respectively, comparing placebo with each
active treatment.
Differences were considered significant when the prob-
ability of type I error was less than 0.05 (two-sided).
Results
Final study population
Because of technical problems during the acquisition phase
(electrode failure at some time point during the sleep
recording), the data from four subjects had to be excluded
from the analysis, leaving a final sample of 18 with a
complete set of PSG recordings. No significant differences
in demographic characteristics were observed between the
initial and the final sample. All 18 participants completed
the trial and were compliant with the study protocol, and all
active treatments were well tolerated.
Subjective effect measures
Significant results were observed for subjective effects as
measured by self-report questionnaires (Pillai’s trace: 1.45;
F=5.98, df=22, 50; p<0.001). Results for the individual
subscales are shown in Table 1.
PSG variables
Sleep initiation and maintenance
Significant results were observed for sleep initiation and
maintenance variables (Pillai’s trace: 1.14; F=3.10, df=20,
52; p=0.001). Significant results were observed for all
sleep latencies. d-Amphetamine induced significant
increases in latencies to stage 1, stage 2, and REM
compared to placebo and to ayahuasca. Additionally, it
showed a trend to increase stage 3 latency. In contrast,
ayahuasca only showed a tendency to increase REM
latency compared to placebo (Table 2).
Sleep maintenance variables also showed significant
results. d-Amphetamine induced significant decreases in
TSP, TST and SEI and significant increases in stage 0, total
wake time and awakenings/TSP as compared to either
placebo or ayahuasca. Ayahuasca did not differ from
placebo in any of these variables (Table 2).
Sleep architecture
Significant results were observed for sleep architecture
variables (Pillai’s trace: 1.28; F=4.60, df=20, 52;
p<0.001). Duration of all sleep stages showed significant
effects except for SWS in percentage of TST and
movement time (in minutes and percentage of TST).
Compared to placebo and ayahuasca, d-amphetamine
induced significant decreases in REM as measured in
minutes or as percentage of TST. Significant decreases in
SWS and significant increases in stage 1 sleep were also
seen after d-amphetamine but only when the former was
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measured in minutes and the latter in percentage. In
addition, d-amphetamine produced significant effects on
stage 2. An increase was found when measured in minutes,
but when expressed as percentage, this difference was only
observed in relation to placebo. Ayahuasca’s significant
effects as compared to placebo consisted in decreases in
REM (in minutes and percentage of TST). A tendency to
increase stage 2 (in minutes and percentage of TST) was
also observed (Table 3).
NREM–REM periods
Significant results were observed for NREM–REM period
variables (Pillai’s trace: 0.89; F=4.97, df=10, 62;
p<0.001). The number of NREM and REM periods as
well as the average duration of NREM periods and sleep
cycles showed significant differences between treatments.
Both active compounds, d-amphetamine and ayahuasca,
decreased the number of periods and increased the duration
Table 1 Acute subjective effects induced by placebo, ayahuasca 1 mg DMT/kg and d-amphetamine 20 mg
Placebo Ayahuasca d-Amphetamine GLM (p values) Adjusted for multiple paired comparisons: Sidak
PLA:AYA PLA:AMP AYA:AMP
HRS
Somaesthesia 0.03 (0.07) 1.36 (0.73) 0.56 (0.44) <0.001 *** *** ***
Affect 0.33 (0.19) 1.43 (0.60) 0.72 (0.33) <0.001 *** *** ***
Perception 0.01 (0.04) 1.61 (0.89) 0.12 (0.17) <0.001 *** ***
Cognition 0.02 (0.07) 1.45 (1.07) 0.34 (0.35) <0.001 *** ** ***
Volition 0.78 (0.63) 1.77 (0.69) 0.88 (0.39) <0.001 *** **
Intensity 0.06 (0.16) 2.25 (0.97) 1.10 (0.79) <0.001 *** *** ***
ARCI
A 0.11 (1.18) 3.06 (1.59) 2.22 (1.93) <0.001 *** **
BG 0.33 (1.19) −0.17 (1.95) 2.83 (2.77) <0.001 ** **
MBG 0.06 (1.86) 3.11 (3.68) 3.33 (2.74) 0.008 * **
PCAG −0.89 (3.83) 0.06 (3.28) −3.72 (3.32) 0.007 *
LSD 0.06 (1.39) 4.61 (2.59) 2.50 (1.62) <0.001 *** ** *
Means (SD) of the scores obtained for the HRS and ARCI questionnaires subscales (n=18), and results of the statistical analysis performed.
PLA placebo, AYA ayahuasca, AMP d-amphetamine, A amphetamine, BG benzedrine group, MBG morphine–benzedrine group, PCAG
pentobarbital–chlorpromazine–alcohol group, LSD lysergic acid diethylamide scale
*p<0.05
**p<0.01
***p<0.001
Table 2 Sleep initiation and maintenance after daytime administration of ayahuasca 1 mg DMT/kg and d-amphetamine 20 mg
Placebo Ayahuasca d-Amphetamine GLM (p values) Adjusted for multiple paired
comparisons: Sidak
PLA:AYA PLA:AMP AYA:AMP
Latency to stage 1 (minutes) 19.39±5.01 13.78±2.64 91.42±16.51 <0.001 *** ***
Latency to stage 2 (minutes) 21.58±5.30 16.97±3.38 109.29±19.82 <0.001 *** ***
Latency to stage 3 (minutes) 21.86±4.00 17.11±2.00 62.89±18.93 0.035 *
REM latency (minutes) 92.44±8.65 113.72±10.55 210.27±18.91 <0.001 * *** **
Total sleep period (minutes) 458.72±5.35 463.56±2.95 361.06±22.22 <0.001 *** ***
Total sleep time (minutes) 444.67±6.48 450.14±3.99 297.97±24.05 <0.001 *** ***
Sleep efficiency (%) 92.52±1.37 93.87±0.83 61.94±4.98 <0.001 *** ***
Wake (minutes) 19.67±5.05 14.42±2.79 116.58±21.79 <0.001 *** ***
Stage 0 (minutes) 13.72±3.30 13.03±2.70 62.94±13.01 <0.001 ** ***
Awakenings/TSP 3.01±0.73 2.81±0.59 18.48±4.12 0.001 ** **
Mean±SEM (n=18)
PLA Placebo, AYA ayahuasca, AMP d-amphetamine
*p<0.10
**p<0.01
***p<0.001
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of NREM periods and sleep cycles as compared to placebo.
However, d-amphetamine’s effects were significantly larger
than those obtained after ayahuasca (Table 4).
Spectral analysis
EEG power spectra
The mean all-night power spectra are presented in Fig. 1.
The values for nights after an active treatment are expressed
as a percentage of the placebo night.
The NREM power spectrum showed differences as a
function of the active compound. Compared to placebo,
values were significantly higher after d-amphetamine in the
high-frequency range (frequencies higher than 15 Hz), while
after ayahuasca, significantly higher values were limited to
the 15–20 Hz frequency band. The spectrum in stage 2 was
very similar to that of NREM, but the SWA spectrum
showed no significant differences between placebo and the
active compounds. In REM, power density was significantly
reduced in comparison to placebo after d-amphetamine in the
2.4–2.8 and 5.6–8.4 Hz frequency ranges.
Table 3 Sleep architecture after daytime administration of ayahuasca 1 mg DMT/kg and d-amphetamine 20 mg
Placebo Ayahuasca d-Amphetamine GLM (p values) Adjusted for multiple paired comparisons:
Sidak
PLA:AYA PLA:AMP AYA:AMP
Stage 1 (minutes) 15.44±2.48 14.44±2.61 21.53±3.54 0.024 *
Stage 1 (%) 3.48±0.57 3.25±0.61 8.08±1.33 <0.001 **** ****
Stage 2 (minutes) 239.58±9.22 261.83±8.37 180.39±17.60 <0.001 * *** ****
Stage 2 (%) 53.71±1.64 58.09±1.68 59.77±2.39 0.015 * **
SWS (minutes) 86.03±3.88 83.94±6.06 58.50±5.51 <0.001 *** ****
SWS (%) 19.40±0.93 18.67±1.37 20.50±1.88 0.572
REM (minutes) 98.28±4.57 82.42±4.14 33.42±5.48 <0.001 *** **** ****
REM (%) 22.19±1.08 18.32±0.93 10.21±1.63 <0.001 *** **** ****
Movement time (minutes) 5.81±0.94 4.61±0.68 4.14±0.82 0.061
Movement time (%) 1.32±0.21 1.02±0.15 1.44±0.28 0.095
All percentages are expressed relative to total sleep time (TST). Mean±SEM (n=18).
PLA Placebo, AYA ayahuasca, AMP d-amphetamine
*p<0.10
**p<0.05
***p<0.01
****p<0.001
Table 4 NREM-REM periods after daytime administration of ayahuasca 1 mg DMT/kg and d-amphetamine 20 mg
Placebo Ayahuasca d-Amphetamine GLM (p values) Adjusted for multiple
paired comparisons: Sidak
PLA:AYA PLA:AMP AYA:AMP
Number NREM periods 4.06±0.17 3.61±0.14 1.72±0.18 <0.001 * *** ***
Number REM periods 4.06±0.17 3.61±0.14 1.56±0.23 <0.001 * *** ***
Average duration NREM
periods (minutes)
82.20±4.13 95.34±3.84 146.51±13.18 <0.001 ** *** **
Average duration REM
periods (minutes)
26.46±1.39 29.64±3.44 19.94±3.30 0.051
Average duration sleep
cycles (minutes)
110.92±4.28 123.12±4.10 210.23±18.92 <0.001 * *** ***
Mean±SEM (n=18)
PLA Placebo, AYA ayahuasca, AMP d-amphetamine
*p<0.05
**p<0.01
***p<0.001
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Dynamics of slow-wave activity
On all nights, either after placebo or active drugs, SWAwas
higher in NREM episodes and lower in REM episodes, and
a declining trend was observed over consecutive NREM
episodes. The dynamics of SWA throughout the night after
all experimental interventions is presented in Fig. 2. A
significant reduction in SWA after d-amphetamine relative
to placebo was obtained in the first cycle (t=2.41, df=14,
p=0.030). On the contrary, a trend to increase SWA
between ayahuasca and placebo in the first cycle was also
evidenced (t=1.82, df=17, p=0.086).
As it has been shown that the delta power in a cycle
is dependent on the number of cycles in that night
(Preud’homme et al. 2000), it has been proposed that to
avoid a potential bias, cycle-by-cycle comparisons should
be conducted on nights with the same number of cycles. As
the number of sleep cycles was significantly affected by the
active treatments, a reanalysis was performed incorporating
only those volunteers who showed the same number of
cycles after all three treatments. No such analysis could be
performed after d-amphetamine as all subjects had a lower
number of cycles in relation to placebo. However, eight
subjects presented the same number of cycles after
ayahuasca and placebo. In this subgroup of volunteers,
SWA showed a significant increase in activity after
ayahuasca as compared to placebo. This increase was
clearly circumscribed to the first cycle (t=2.78, df=7,
p=0.027).
Dynamics of spindle frequency activity
The typical pattern of SFA with low values in REM
episodes, and a higher level, U-shaped pattern (with lowest
values coinciding with highest values of SWA) in NREM
episodes, was observed after all three treatments. No
significant changes were observed in the amount of SFA
between any active treatment and placebo (Fig. 2).
Dynamics of slow activity in EOG channels (DEA) during
REM sleep
Slow activity in EOG channels during REM sleep did not
show any significant changes when comparing the night
after placebo with the nights after active compounds.
Subjective sleep and awakening quality
Significant results were observed for subjective sleep and
awakening quality variables (Pillai’s trace: 0.81; F=4.21,
df=10, 62; p<0.001). No significant treatment effects
were observed for somatic complaints. However, after
d-amphetamine, there was a significant impairment of the
global score and the subjective sleep quality score in
comparison to placebo and ayahuasca. Significant effects
were also obtained in subjective sleep latency and subjec-
tive sleep efficiency. d-Amphetamine induced an increase
of the former and a decrease of the latter in comparison to
placebo and ayahuasca (Table 5).
Fig. 1 EEG power density
(C4A1-derivation) in non-REM
sleep (stages 1, 2, 3 and 4) stage
2 (S2), slow-wave sleep (stages
3 and 4) and REM sleep after
daytime administration of aya-
huasca 1 mg DMT/kg and d-
amphetamine 20 mg. For each
frequency bin (n=18), means
are expressed as a percentage of
the corresponding value after
placebo (horizontal dashed lines
at 0%). Asterisks at the bottom
of the panels indicate frequency
bins which differ significantly
from placebo (p<0.05, t test for
repeated measures)
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Table 5 Subjective sleep and awakening quality after daytime administration of ayahuasca 1 mg DMT/kg and d-amphetamine 20 mg
Placebo Ayahuasca d-Amphetamine GLM (p values) Adjusted for multiple paired comparisons: Sidak
PLA:AYA PLA:AMP AYA:AMP
SSA-T 34.67±1.22 33.72±1.02 41.44±1.60 <0.001 ** *
SSA-1 13.89±0.64 14.28±0.73 19.67±0.85 <0.001 ** **
SSA-2 15.28±0.76 13.94±0.50 16.11±0.85 0.047
SSA-3 5.50±0.20 5.50±0.23 5.67±0.24 0.715
SSL (minutes) 31.56±5.80 37.33±7.52 115.22±18.19 <0.001 * *
SSE (minutes) 85.64±3.02 85.43±2.52 59.25±5.64 <0.001 ** **
Mean±SEM (n=18)
SSA Self-assessment scale for sleep and awakening quality: T=total score, 1 subjective sleep quality, 2 subjective awakening quality, 3 somatic
complains; SSL subjective sleep latency, SSE subjective sleep efficiency, PLA placebo, AYA ayahuasca, AMP d-amphetamine
*p<0.01
**p<0.001
Fig. 2 Time course of EEG slow-wave activity (SWA, 0.5–4.0 Hz
range; C4-A1-derivation) and spindle frequency activity (SFA, 11.0–
15.0 Hz range; C4-A1-derivation) plotted after daytime administration
of ayahuasca 1 mg DMT/kg and d-amphetamine 20 mg (continuous
curves) against placebo (dashed curves). For each subject, individual
NREM episodes were subdivided into 20 equal time bins. Data were
averaged across subjects (n=18, for ayahuasca and n=14 for d-
amphetamine) and plotted against the mean timing of NREM sleep.
Dashed vertical lines delimit NREM episodes. Triangles indicate
significant AUC increases or decreases in relation to placebo for a
given NREM episode. Ayahuasca showed a trend increase in the first
NREM episode (t test for repeated measures: p=0.086; upper left
panel), which became significant (p=0.027) when the analysis was
performed with only those volunteers who showed the same number of
cycles after ayahuasca and placebo (n=8; middle panel)
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Discussion
Daytime drug administration in the present study caused
significant psychotropic effects as measured by self-report
questionnaires. d-Amphetamine showed a pattern typical of
the psychostimulants with high scores in the ARCI-A,
ARCI-BG and ARCI-MBG subscales (Martin et al. 1971).
Similarly, ayahuasca showed significant effects in the
ARCI-A and ARCI-MBG subscales, which measure
amphetamine-like stimulatory effects and euphoria, respec-
tively, but not in the ARCI-BG which measures intellectual
efficiency. Both drugs induced somatic–dysphoric effects as
measured by the ARCI-LSD scale. The most relevant
differences between the two drugs were the significant
increases in the HRS-perception and HRS-volition sub-
scales observed for ayahuasca only and which reflect
modifications in perception and increased impairment,
respectively. The overall pattern of subjective effects
induced by ayahuasca replicates results found by our group
in a previous study (Riba et al. 2003).
Regarding sleep measures, d-amphetamine caused a
clear deterioration of subjective sleep quality and objective
sleep measures, delaying sleep initiation, disrupting sleep
maintenance, increasing light sleep, and decreasing the
duration of REM sleep and the number of non-REM and
REM cycles. These effects are in line with the well-
documented effects of amphetamine on sleep. This com-
pound and its derivatives suppress REM sleep, and as the
doses rise, vigilance is increased and sleep continuity is
disturbed (Saletu et al. 1989).
Ayahuasca, on the other hand, did not induce a
deterioration of sleep, and no significant effects on sleep
initiation or maintenance variables were evidenced. How-
ever, like d-amphetamine, ayahuasca increased stage 2,
decreased REM stage duration and showed a trend to
increase REM latency. Furthermore, we observed decreases
in the number of non-REM and REM periods and increases
in the average duration of non-REM periods and sleep
cycles, but these were of less magnitude than after
d-amphetamine. Also in contrast with d-amphetamine, no
subjectively measured deterioration was observed com-
pared to placebo.
As evidenced by results in the present and prior (Riba et
al. 2003) studies, psychedelics have the capacity to induce
increases in activation that can be measured by self-report
questionnaires and by EEG (Riba et al. 2002). We had thus
postulated that both ayahuasca and d-amphetamine would
impair sleep initiation and maintenance variables and would
suppress REM. The mentioned trend to increase REM
latency and the significant decrease in duration were in fact
the only common effects observed by means of PSG. In this
respect, it is worth mentioning that Gouzoulis et al. (1992)
reported the complete suppression of REM after the
nighttime administration of MDE, a compound with a
chemical structure related to both amphetamines and
psychedelic phenylethylamines.
To our knowledge, the sleep effects of pharmacological-
ly closer compounds, i.e., the classical serotonergic psy-
chedelics, have been studied in very few reports, most of
which were published in the 1960s. Muzio et al. (1966)
administered LSD in doses ranging from 0.08 to 73 μg/kg
to 12 volunteers on a total of 36 nights and compared the
data obtained with that from 69 control nights in the same
subjects. The drug was administered orally just before sleep
or after 1 h of sleep. These authors found LSD increased
the duration of the first or second REM period. They also
observed that when an abnormal excess of REM sleep had
been induced early in the night there was a below-normal
amount of REM sleep during the second half of the night
(a kind of reverse ‘rebound’ within the same night). This
acute facilitation of the REM stage in humans was also
reported by Green (1965) and by Torda (1968). Such
findings clearly differ from those obtained in the present
study. However, in the mentioned studies, LSD-induced
REM increases were always observed after the immediate
administration of the compound, whereas in our study
ayahuasca was administered at 12:00 noon. Given the
complex chemical nature of ayahuasca, other alkaloids
besides DMT may have played a role in the effects
observed on REM. While harmine, an abundant and
pharmacologically potent β-carboline, appears to undergo
an intense first-pass metabolization, substantial levels of
THH can be measured in plasma after oral ayahuasca (Riba
et al. 2003). THH is a weaker MAO inhibitor than harmine
but a stronger serotonin reuptake inhibitor (Buckholtz and
Boggan 1977a, b). Reversible MAO inhibitors such as
moclobemide (Blois and Gaillard 1990) and selective
serotonin reuptake inhibitors (SSRI), such as paroxetine
(Hicks et al. 2002), have all been mainly characterized by
their ability to decrease REM sleep and to increase stage 2.
It is interesting to note that the sleep effects after SSRIs
have been reported to be more evident after morning than
after evening drug administration (Barbanoj et al. 2005).
Despite the presence of MAOIs and SSRIs in ayahua-
sca, its acute pharmacological effects in humans are those
of the classical serotonergic psychedelics acting at the
5-HT1A and 5-HT2A/C sites. The role of these receptors in
sleep physiology has been the subject of many studies over
the last 40 years. The electrical activity of raphe neurons
and the release of 5-HT are increased during waking and
decreased during sleep (McGinty and Harper 1976). The
available evidence indicates a role for 5-HT1A receptors on
REM sleep regulation and for 5-HT2A/C receptors in SWS
regulation. Thus, selective activation of somatodendritic
5-HT1A receptors in the dorsal raphe induces an increase of
REM sleep, although activation of the postsynaptic 5-HT1A
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receptors at the level of cholinergic neurons located in
tegmentum nuclei decreases REM sleep occurrence
(reviewed in Monti and Monti (2000)). 5-HT1A agonists
have been shown to suppress REM sleep (Driver et al.
1995; Gillin et al. 1994). Regarding SWS, drugs antagonis-
ing 5-HT2A or 5-HT2C demonstrate an enhancing effect on
SWS (Landolt et al. 1999; Sharpley et al. 1994), whereas
5-HT2C agonists appear to lower SWS (Katsuda et al. 1993).
Spectral analysis showed that d-amphetamine leads to
increases in power in the high-frequency range (higher than
15 Hz), an effect mainly observed during stage 2. In
addition, the amount of SWA in the first night cycle was
also reduced. To our knowledge, there are no published
data on d-amphetamine effects on night EEG power
spectra. However, the above effects could be expected if
we take into account the alerting pattern associated with the
morning intake of the d-amphetamine. The first effect
would be related to the vigilance promoting effects
associated to increases in power in the higher frequencies
(Coull 1998). The second effect would be related to
attenuation of sleep propensity associated with wakefulness
(Johns 2002). Similar EEG power spectra changes have
been reported after caffeine 200 mg intake in the morning
(Landolt et al. 1995).
Ayahuasca also showed increases in power in the high
frequencies, although these were limited to the 15–20
frequency range. In contrast with d-amphetamine, an
increase in slow-wave power was observed in the first
night cycle. This finding was unexpected, given the SWS
decreasing effects that have been associated with 5-HT2
agonism (Katsuda et al. 1993). From a neurochemical
perspective, these results could be explained by the agonist
properties of DMT at the 5-HT1A sites (Seifritz et al. 1996)
or through a functional desensitization of the 5-HT2
(Saucier et al. 1998). Activation of 5-HT1A receptors seems
to result in a decrease of neural activity at 5-HT2 sites. This
might be because of either activation of presynaptic
autoreceptors within the dorsal raphe nucleus leading to a
decrease of activity at postsynaptic projection sites
(Sprouse and Aghajanian 1987) and/or activation of
postsynaptic 5-HT1A receptors which would exert a
modulatory inhibition of 5-HT2 receptors (Araneda and
Andrade 1991). An alternative explanation is that after the
acute effects of ayahuasca, ‘sleep pressure’ is increased.
The increases observed in SWS are typical of certain
situations. After sleep deprivation, SWS activity increases
are observed limited to the first night cycle (Borbély et al.
1981). Similarly, according to a recent meta-analysis
(Driver and Taylor 2000), physical exercise has also been
found to induce increases in SWS, reductions in REM and
increases in REM latency. The changes observed in SWS
could reflect a reaction to the physical and mental stress
induced by the drug, as tiredness is frequent after
ayahuasca and cortisol levels are augmented in the course
of the experience (Callaway et al. 1999).
In summary, the present results did not evidence a
deterioration of sleep quality after daytime consumption of
ayahuasca. Sleep architecture showed ayahuasca to inhibit
REM and spectral analysis demonstrated increases in slow-
wave activity in the first night cycle. Results suggest an
interaction between serotonergic psychedelics and brain
circuits modulating REM and SWS.
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